Your browser doesn't support javascript.
loading
Impact of COVID-19 monoclonal antibodies on outcomes of COVID-19 infection in hematopoietic stem cell transplant and chimeric antigen receptor therapy recipients.
Hahn, Elizabeth H; Li, Hong; Sauter, Craig S; Mossad, Sherif B.
Afiliación
  • Hahn EH; Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Li H; Department of Hematology and Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Sauter CS; Department of Hematology and Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Mossad SB; Department of Infectious Disease, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Transpl Infect Dis ; 26(4): e14322, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38937864
ABSTRACT

BACKGROUND:

Hematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T-cell therapy (CAR-T) recipients are at higher risk of serious complications of COVID-19 infection than the general population. Though there is evidence that monoclonal antibodies (MCA) against COVID-19 reduce the risk of death and hospitalization in the general population, data regarding their efficacy in HSCT and CAR-T recipients remains scarce.

METHODS:

We conducted a retrospective review of HSCT and CAR-T recipients to compare 30-day outcomes between patients who did and did not receive MCA after their first episode of COVID-19 between May 1, 2020 and December 31, 2022. Outcomes were defined as the most severe complication experienced out of the following 30-day emergency department visit, hospitalization, intensive care unit admission, and death after COVID-19 infection.

RESULTS:

We identified 166 patients comprised of 53.6% allogeneic HSCT, 35.5% autologous HSCT, and 10.8% CAR-T recipients; 107 had received a COVID-19 vaccine >2 weeks prior to testing positive, and 40 were treated with MCA. After adjusting for age, presence of symptoms at the initial positive test, and COVID-19 vaccination status, patients who did not receive MCA were five times more likely to develop complications after COVID-19 infection (adjusted odds ratio 5.0 [95% CI, 1.9-12.8], p = .001).

CONCLUSION:

HSCT and CAR-T recipients who received MCA following COVID-19 infection were far less likely to develop COVID-related complications than those who did not receive MCA, regardless of vaccination status. This underscores the potential benefit of developing novel MCA with efficacy against circulating COVID-19 strains.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Receptores Quiméricos de Antígenos / SARS-CoV-2 / COVID-19 / Anticuerpos Monoclonales Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Transpl Infect Dis Asunto de la revista: TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Receptores Quiméricos de Antígenos / SARS-CoV-2 / COVID-19 / Anticuerpos Monoclonales Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Transpl Infect Dis Asunto de la revista: TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Dinamarca